Journal
OBSTETRICS AND GYNECOLOGY
Volume 138, Issue 3, Pages 338-347Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/AOG.0000000000004513
Keywords
-
Categories
Funding
- Merck
- Ferring
- Guerbet
Ask authors/readers for more resources
Randomized controlled trials are crucial in evidence-based medicine, but compromised data integrity and research misconduct pose risks to patients and undermine the authority of this scientific tool. There is a need for better methods to detect and prevent research misconduct, as well as improved mechanisms for investigating data manipulation and prioritizing patient and reader interests over trial authors and institutions.
Randomized controlled trials (RCTs) serve as the pillar of evidence-based medicine and guide medical practice. Compromised data integrity in RCTs undermines the authority of this valuable tool for science and puts patients at risk. Although a large number of retractions due to data issues in obstetrics and gynecology have occurred in the past few years, many problematic RCTs could still go uncovered because in general there is insufficient willingness to envisage and confront research misconduct. In this article, we discuss the necessity of assessing research misconduct, summarize methods that have been applied in detecting previous cases of misconduct, and propose potential solutions. There is no established mechanism to monitor feedback on published articles and the current system that handles potential research misconduct is unsatisfactory. Fortunately, there are methods to assess data integrity in RCTs both with and without individual participant data. Investigations into research misconduct can be facilitated by assessing all publications from a leading author or author group to identify duplication and patterns of ongoing misconduct. There is a pressing need to improve the mechanism that investigates data manipulation. The mechanism that handles misconduct should prioritize the interests of patients and readers rather than trial authors and their institutions. An equally urgent issue is to establish mechanisms that prevent compromised trials from polluting evidence synthesis or misguiding practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available